{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-058228","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.943836+00:00","generated_at":"2026-06-25T22:01:30.852715+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Journey Medical reports record Q1 revenue of $23.3M, up 117% YoY; net loss of $1.4M","bullets":["Record net product revenue $20.8M (+94% YoY); $2.5M milestone from Maruho for QBREXZA Japan approval.","Net loss of $1.4M ($0.08/share) vs net income $0.3M ($0.03) in Q1 2021; adjusted EBITDA $2.3M vs $1.2M.","First patient dosed in Phase 3 trial for DFD-29 for papulopustular rosacea; one additional product launch planned in H2 2022.","Expanded product portfolio with Amzeeq and Zilxi launches; now 9 marketed prescription dermatology products."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-058228","json":"https://secwatch.observer/filing/0001104659-22-058228.json","markdown":"https://secwatch.observer/filing/0001104659-22-058228.md","text":"https://secwatch.observer/filing/0001104659-22-058228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465922058228/0001104659-22-058228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465922058228/tm2214972d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:01:30.852715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}